Abacus FCF Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.58M | Sell |
59,974
-22,600
| -27% | -$2.98M | 1.39% | 31 |
|
|
2026
Q1 | $11.5M | Sell |
82,574
-59,400
| -42% | -$8.32M | 2.59% | 10 |
|
|
2025
Q4 | $17.4M | Buy |
141,974
+3,300
| +2% | +$401K | 2.28% | 12 |
|
|
2025
Q3 | $15.4M | Sell |
138,674
-26,340
| -16% | -$2.99M | 2.05% | 24 |
|
|
2025
Q2 | $18.3M | Buy |
165,014
+2,828
| +2% | +$301K | 2.56% | 10 |
|
|
2025
Q1 | $18.2M | Buy |
162,186
+36,309
| +29% | +$3.75M | 2.85% | 6 |
|
|
2024
Q4 | $11.6M | Buy |
125,877
+50,408
| +67% | +$4.54M | 1.53% | 11 |
|
|
2024
Q3 | $6.33M | Buy |
75,469
+5,837
| +8% | +$445K | 1.47% | 14 |
|
|
2024
Q2 | $4.78M | Buy |
69,632
+6,749
| +11% | +$450K | 1.19% | 15 |
|
|
2024
Q1 | $4.61M | Buy |
62,883
+5,077
| +9% | +$390K | 1.15% | 23 |
|
|
2023
Q4 | $4.68M | Buy |
57,806
+34,349
| +146% | +$2.67M | 1.36% | 17 |
|
|
2023
Q3 | $1.76M | Sell |
23,457
-635
| -3% | -$48.8K | 0.93% | 28 |
|
|
2023
Q2 | $1.86M | Sell |
24,092
-158
| -0.7% | -$12.6K | 0.94% | 33 |
|
|
2023
Q1 | $2.01M | Buy |
24,250
+10,633
| +78% | +$881K | 1.08% | 20 |
|
|
2022
Q4 | $1.17M | Sell |
13,617
-306
| -2% | -$24.2K | 0.76% | 43 |
|
|
2022
Q3 | $858K | Sell |
13,923
-1,020
| -7% | -$64.3K | 0.59% | 67 |
|
|
2022
Q2 | $924K | Sell |
14,943
-8,937
| -37% | -$553K | 0.57% | 69 |
|
|
2022
Q1 | $1.42M | Buy |
+23,880
| New | +$1.53M | 0.48% | 78 |
|
|
2020
Q4 | – | Sell |
-27,033
| Closed | -$1.73M | – | 93 |
|
|
2020
Q3 | $1.73M | Buy |
27,033
+9,702
| +56% | +$673K | 0.93% | 69 |
|
|
2020
Q2 | $1.32M | Sell |
17,331
-770
| -4% | -$59K | 1.26% | 27 |
|
|
2020
Q1 | $1.32M | Buy |
+18,101
| New | +$1.25M | 1.51% | 19 |
|
|
2017
Q2 | – | Sell |
-1,323
| Closed | -$90K | – | 109 |
|
|
2017
Q1 | $90K | Buy |
1,323
+624
| +89% | +$43.9K | 0.74% | 97 |
|
|
2016
Q4 | $50K | Buy |
699
+395
| +130% | +$29.4K | 0.83% | 92 |
|
|
2016
Q3 | $24K | Buy |
+304
| New | +$24.7K | 0.96% | 85 |
|
|
2016
Q2 | – | Sell |
-15,441
| Closed | -$1.42M | – | 109 |
|
|
2016
Q1 | $1.42M | Sell |
15,441
-4,430
| -22% | -$399K | 0.81% | 93 |
|
|
2015
Q4 | $2.01M | Buy |
19,871
+369
| +2% | +$38.4K | 0.92% | 88 |
|
|
2015
Q3 | $1.92M | Sell |
19,502
-1,476
| -7% | -$164K | 0.99% | 79 |
|
|
2015
Q2 | $2.46M | Sell |
20,978
-420
| -2% | -$45.9K | 1.07% | 31 |
|
|
2015
Q1 | $2.1M | Buy |
+21,398
| New | +$2.17M | 1.03% | 87 |
|
Other funds holding GILD
Abacus FCF Advisors's GILD Position: Q2 2026 in Review
Abacus FCF Advisors reduced its Gilead Sciences (GILD) stake by 27% in Q2 2026, selling an estimated $2.98M and leaving 59,974 shares worth $7.58M. The position accounts for 1.39% of the portfolio, ranked #31.
Abacus FCF Advisors first reported a position in GILD in Q1 2015 and has held it in 29 quarters since. The position peaked at $18.3M in Q2 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Abacus FCF Advisors held 59,974 shares of Gilead Sciences worth $7.58M as of Q2 2026.
- Abacus FCF Advisors sold 22,600 Gilead Sciences shares in Q2 2026, an estimated $2.98M.
- Gilead Sciences made up 1.39% of Abacus FCF Advisors's portfolio in Q2 2026, its #31 holding.
- Abacus FCF Advisors first reported a position in Gilead Sciences in Q1 2015 and has held it in 29 quarters since.
- Abacus FCF Advisors's Gilead Sciences position peaked at $18.3M in Q2 2025.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Abacus FCF Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.